10X1000-TECH
5.3.2024 14:28:31 CET | Business Wire | Press release
The Global Digital Talent Community 10x1000 Tech for Inclusion (“10x1000”) and FINOLAB, a Tokyo-based fintech office and business community, have entered into a collaborative effort to enhance digital capacity and drive digital economic growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305260615/en/
The Global Digital Talent Community 10x1000 Tech for Inclusion (“10x1000”) and FINOLAB have entered into a collaborative effort to enhance digital capacity and drive digital economic growth. (Photo: Business Wire)
Pursuant to a signed Memorandum of Understanding (MoU), FINOLAB will collaborate with 10x1000 to identify and invite qualified participants through its network of member institutions, partners, affiliates, and other stakeholders to participate in the learning programs provided by 10x1000. Participants will be afforded the opportunity to serve as both learners and industry experts.
Additionally, the two organizations will work together to develop learning content that highlights and promotes the digital landscape and opportunities in Japan and drive knowledge sharing through their respective networks.
The MoU was signed by Jennifer Tan, Program Head for 10x1000 Tech for Inclusion, and Makoto Shibata, Head of FINOLAB and Chief Community Officer at FINOLAB. The signing ceremony was witnessed by Sopnendu Mohanty, Chief Fintech Officer at the Monetary Authority of Singapore, Leiming Chen, Chief Sustainability Officer of Ant International and Senior Vice President at Ant Group, and Chie Ito, Chief Executive Officer of FINOLAB.
“We are honored to join hands with FINOLAB to extend the network of 10x1000 in terms of both learners and lecturers, which will benefit the community profoundly. This collaboration marks a pivotal moment in our journey towards cultivating a vibrant and inclusive talent development ecosystem, where innovation knows no boundaries,” said Ms. Tan.
“Our members would benefit immensely from the knowledge accumulation of 10x1000 and we may also be able to contribute our experiences in Japan to the 10x1000 community members. The collaboration would be an appropriate opportunity for all of us to appreciate the true value of open innovation,” commented Mr. Shibata.
By the year 2023, 10x1000 has certified a total of 6,243 learners from over 100 countries and regions. The Philippines, Indonesia, Thailand, Bangladesh, and Nigeria were the top five countries from which most learners came. Of the certified learners, females accounted for 49% of the total learner base. It is noteworthy that the certified learners represent more than 2,000 organizations, and nearly 80% of them are micro, small, or medium-sized enterprises (MSMEs).
About 10x1000 Tech for Inclusion
10x1000 Tech for Inclusion is an open and global learning community that enables learners to become drivers of digital economic growth. Its mission is to nurture and inspire at least 1,000 emerging talents and tech leaders each year for the next ten years. 10x1000 is a philanthropic initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
About FINOLAB
FINOLAB is a membership business community and an office space located in the heart of international financial district in Tokyo to promote FinTech ecosystem and open innovation. Launched in Feb. 2016 by Mitsubishi Estate and Dentsu Group as the first FinTech Center in Japan, it consists of stakeholders, including startups, corporates, and regulators.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305260615/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
